Incident Use of Hydroxychloroquine for the Treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus During the COVID-19 Pandemic.
Núria Mercadé-BesoraYuchen GuoMike DuXintong LiJuan Manuel Ramírez-AnguitaAlberto MorenoAntónio ValenteFelipe VillalobosIek Leng ChengLucía A Carrasco-RibellesMaaike M H van SwietenManon MerkelbachMary MagoyaPaolo LasalviaPau Pericàs-PulidoPaul BergPauline Bosco-LévyRoberto LilliniRogerio RibeiroTrinamjot Kaur BaggaVittoria RamellaSara KhalidMiguel Angel MayerAngela LeisAnnika M JödickeEdward BurnDaniel Prieto AlhambraMartí CatalàAlbert Prats-UribePublished in: Arthritis care & research (2024)
Use of HCQ increased dramatically in the general population in both Spain and the United States during March and April 2020. Whereas Spain returned to prepandemic rates after the first wave, use of HCQ remained high and followed waves of COVID-19 in the United States. However, we found no evidence of general shortages in the use of HCQ for both RA and SLE in the United States.